Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas

References

• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714. doi:10.1182/blood-2018-11-881268
   PubMed Web of Science ®Google Scholar
• Pinter-Brown LC. Diagnosis and management of cutaneous B-cell lymphoma. Dermatol Clin. 2015;33(4):835–840. doi:10.1016/j.det.2015.05.003
   Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–5073. doi:10.1182/blood-2008-10-184168
   PubMed Web of Science ®Google Scholar
• Perez M, Pacchiarotti A, Frontani M, et al. Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. Br J Dermatol. 2010;162(3):611–618. doi:10.1111/j.1365-2133.2009.09576.x
   Web of Science ®Google Scholar
• Perrone S, D’Elia GM, Annechini G, Pulsoni A. Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016006. doi:10.4084/mjhid.2016.006
   Web of Science ®Google Scholar
• Ponzoni M, Ferreri AJ. Bacteria associated with marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1–2):32–40. doi:10.1016/j.beha.2017.01.001
   Web of Science ®Google Scholar
• Foster LH, Portell CA. The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas. Curr Treat Options Oncol. 2015;16(6):28. doi:10.1007/s11864-015-0344-6
   Web of Science ®Google Scholar
• Bende RJ, van Maldegem F, van Noesel CJ. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica. 2009;94(8):1109–1123. doi:10.3324/haematol.2009.005983
   PubMed Web of Science ®Google Scholar
• Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–3044. doi:10.1182/blood-2005-09-3679
   PubMed Web of Science ®Google Scholar
• Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25(10):2025–2030. doi:10.1093/annonc/mdu365
   PubMed Web of Science ®Google Scholar
• Chandler JB, Waldman R, Sloan SB, Rose MG, Wong EY. Cutaneous marginal zone lymphoma following anthrax vaccination. Ann Hematol. 2020. doi:10.1007/s00277-020-04336-4
   Web of Science ®Google Scholar
• Shinohara MM, Nguyen J, Gardner J, Rosenbach M, Elenitsas R. The histopathologic spectrum of decorative tattoo complications. J Cutan Pathol. 2012;39(12):1110–1118. doi:10.1111/cup.12023
   Web of Science ®Google Scholar
• Palmedo G, Hantschke M, Rütten A, et al. Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH/BCL2 and the t(14;18)(q32;q21) IGH/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma? Am J Dermatopathol. 2007;29(3):231–236. doi:10.1097/DAD.0b013e31804795a6
   Web of Science ®Google Scholar
• Tang X, Tang J, Liu W, Wang L. Primary cutaneous marginal zone B-cell lymphoma with unusual manifestation and spontaneous regression. Indian J Dermatol Venereol Leprol. 2020;86(4):428–431. doi:10.4103/ijdvl.IJDVL_516_19
   Web of Science ®Google Scholar
• Franco R, Fernández-Vázquez A, Mollejo M, et al. Cutaneous presentation of follicular lymphomas. Mod Pathol. 2001;14(9):913–919. doi:10.1038/modpathol.3880411
   Web of Science ®Google Scholar
• Vitiello P, Sica A, Ronchi A, Caccavale S, Franco R, Argenziano G. Primary cutaneous B-cell lymphomas: an update. Front Oncol. 2020;10:651. doi:10.3389/fonc.2020.00651
   PubMed Web of Science ®Google Scholar
• Piccolo V, Mascolo M, Russo T, Staibano S, Argenziano G. Dermoscopy of primary cutaneous B-cell lymphoma (PCBCL). J Am Acad Dermatol. 2016;75(4):e137–e139. doi:10.1016/j.jaad.2016.02.1217
   Web of Science ®Google Scholar
• Piccolo V, Russo T, Agozzino M, et al. Dermoscopy of cutaneous lymphoproliferative disorders: where are we now? Dermatology. 2018;234:131–136. doi:10.1159/000490412
   Web of Science ®Google Scholar
• Geller S, Marghoob AA, Scope A, Braun RP, Myskowski PL. Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma. J Eur Acad Dermatol Venereol. 2018;32(1):53–56. doi:10.1111/jdv.14549
   Web of Science ®Google Scholar
• Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol. 1999;23(1):88–96. doi:10.1097/00000478-199901000-00010
   PubMed Web of Science ®Google Scholar
• Arai E, Okubo H, Tsuchida T, Kitamura K, Katayama I. Pseudolymphomatous folliculitis: a clinicopathologic study of 15 cases of cutaneous pseudolymphoma with follicular invasion. Am J Surg Pathol. 1999;23:1313–1319. doi:10.1097/00000478-199911000-00001
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2018;93:1427–1430. doi:10.1002/ajh.25224
   PubMed Web of Science ®Google Scholar
• Cho-Vega JH, Vega F, Rassidakis G, et al. Primary cutaneous marginal zone B cell lymphoma. Am J Clin Pathol. 2006;125:S38–S49. doi:10.1309/CVFYBQNMX1PKNAA7
   PubMedGoogle Scholar
• Patsinakidis N, Kautz O, Gibbs BF, Raap U. Lupus erythematosus tumidus: clinical perspectives. Clin Cosmet Investig Dermatol. 2019;12:707–719. doi:10.2147/CCID.S166723
   Web of Science ®Google Scholar
• Rémy-Leroux V, Léonard F, Lambert D, et al. Comparison of histopathologic-clinical characteristics of Jessner’s lymphocytic infiltration of the skin and lupus erythematosus tumidus: multicenter study of 46 cases. J Am Acad Dermatol. 2008;58(2):217–223. doi:10.1016/j.jaad.2007.09.039
   Web of Science ®Google Scholar
• Lallas A, Argenziano G, Apalla Z, et al. Dermoscopic patterns of common facial inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2014;28(5):609–614. doi:10.1111/jdv.12146
   PubMed Web of Science ®Google Scholar
• Tees MT, Flinn IW. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. Expert Rev Hematol. 2017;10(2):137–146. doi:10.1080/17474086.2017.1270203
   PubMed Web of Science ®Google Scholar
• Gusdorf L, Lipsker D. Schnitzler syndrome: a review. Curr Rheumatol Rep. 2017;19(8):46. doi:10.1007/s11926-017-0673-5
   PubMed Web of Science ®Google Scholar
• Torne R, Su WP, Winkelmann RK, Smolle J, Kerl H. Clinicopathologic study of cutaneous plasmacytoma. Int J Dermatol. 1990;29(8):562–566. doi:10.1111/j.1365-4362.1990.tb03469.x
   Web of Science ®Google Scholar
• Gru AA, Wick MR, Eid M. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):39–48. doi:10.12788/j.sder.2018.006
   Web of Science ®Google Scholar
• Carlsen ED, Swerdlow SH, Cook JR, et al. Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases. Am J Surg Pathol. 2019;43:1403–1412. doi:10.1097/PAS.0000000000001363
   Web of Science ®Google Scholar
• Cerroni L, Signoretti S, Höfler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol. 1997;21:1307–1315. doi:10.1097/00000478-199711000-00005
   PubMed Web of Science ®Google Scholar
• Magro CM, Olson LC. Small cell lymphocytic variant of marginal zone lymphoma: a distinct form of marginal zone lymphoma derived from naïve B cells as a cutaneous counterpart to the naïve marginal zone lymphoma of splenic origin. Ann Diagn Pathol. 2018;34:116–121. doi:10.1016/j.anndiagpath.2018.02.006
   Web of Science ®Google Scholar
• LeBoit PE, McNutt NS, Reed JA, et al. Primary cutaneous immunocytoma a B‐cell lymphoma that can easily be mistaken for cutaneous lymphoid hyperplasia. Am J Surg Pathol. 1994;18:969. doi:10.1097/00000478-199410000-00001
   PubMed Web of Science ®Google Scholar
• Rijlaarsdam JU, van der Putte SCJ, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology. 1993;23:117–125. doi:10.1111/j.1365-2559.1993.tb00469.x
   PubMed Web of Science ®Google Scholar
• Turbiner Geyer J, Ferry JA, Longtine JA, et al. Characteristics of cutaneous marginal zone lymphomas with marked plasmacytic differentiation and a T cell‐rich background. Am J Clin Pathol. 2010;133:59–69. doi:10.1309/AJCPW64FFBTTPKFN
   Web of Science ®Google Scholar
• Magro CM, Yang A, Fraga G. Blastic marginal zone lymphoma: a clinical and pathological study of 8 cases and review of the literature. Am J Dermatopathol. 2013;35:319–326. doi:10.1097/DAD.0b013e318267495f
   Web of Science ®Google Scholar
• Walsh NM, Lano IM, Green P, et al. AL amyloidoma of the skin/subcutis: cutaneous amyloidosis, plasma cell dyscrasia or a manifestation of primary cutaneous marginal zone lymphoma? Am J Surg Pathol. 2017;41:1069–1076. doi:10.1097/PAS.0000000000000861
   Web of Science ®Google Scholar
• Ueberdiek S, Kempf W, Kretschmer L, Schon MP, Mitteldorf C. AL‐amyloidoma of the skin – a rare manifestation of primary cutaneous marginal zone lymphoma. Am J Dermatopathol. 2019;41:518–521. doi:10.1097/DAD.0000000000001368
   Web of Science ®Google Scholar
• Verdanet E, Dereure O, René C, et al. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas. Histopathology. 2017;71(4):648–660. doi:10.1111/his.13279
   Web of Science ®Google Scholar
• Kempf W, Kerl H, Kutzner H. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: a crucial role and a new lymphoma paradigm. Am J Dermatopathol. 2010;32(2):194–196. doi:10.1097/DAD.0b013e3181aff9b3
   Web of Science ®Google Scholar
• Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830–1841. doi:10.1097/PAS.0b013e3181f72835
   Web of Science ®Google Scholar
• Franco R, Camacho FI, Fernández-Vázquez A, et al. IgV(H) and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens. Mod Pathol. 2004;17(6):623–630. doi:10.1038/modpathol.3800106
   Web of Science ®Google Scholar
• Albano D, Durmo R, Treglia G, Giubbini R, Bertagna F. 18F-FDG PET/CT or PET Role in MALT Lymphoma: an open issue not yet solved - a critical review. Clin Lymphoma Myeloma Leuk. 2020;20(3):137–146. doi:10.1016/j.clml.2019.10.006
   PubMed Web of Science ®Google Scholar
• Merli M, Frigeni M, Alric L, et al. Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas. Oncologist. 2019;24(8):e720–e729. doi:10.1634/theoncologist.2018-0331
   PubMed Web of Science ®Google Scholar
• Tonziello G, Pisaturo M, Sica A, et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2013;41(1):225–229. doi:10.1007/s15010-012-0305-y
   PubMed Web of Science ®Google Scholar
• Pisaturo M, Guastafierro S, Filippini P, et al. Absence of occult HCV infection in patients experiencing an immunodepression condition. Infez Med. 2013;21(4):296–301.
   Google Scholar
• Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44(1):49–54. doi:10.1016/j.dld.2011.07.016
   PubMedGoogle Scholar
• Merli M, Defrancesco I, Visco C, et al. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;28:1–7.
   Google Scholar
• Bagaglio S, Uberti-Foppa C, Sagnelli C, et al. HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. Infection. 2020;48(4):553–558. doi:10.1007/s15010-020-01434-3
   Web of Science ®Google Scholar
• Sica A, Casale D, Rossi G, et al. The impact of the SARS-CoV-2 infection, with special reference to the haematological setting. J Med Virol. 2020;93(1):223–233. doi:10.1002/jmv.26197
   Web of Science ®Google Scholar
• Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of cancer (EORTC). Blood. 2007;110:479‐484. doi:10.1182/blood-2006-10-054601
   Web of Science ®Google Scholar
• Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian study group for cutaneous lymphomas. J Clin Oncol. 2006;24(9):1376–1382. doi:10.1200/JCO.2005.03.6285
   Web of Science ®Google Scholar
• Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the international extranodal lymphoma study group (IELSG 11). Ann Hematol. 2011;90(4):401–408. doi:10.1007/s00277-010-1083-1
   Web of Science ®Google Scholar
• Reginelli A, Urraro F, Sangiovanni A, et al. Extranodal lymphomas: a pictorial review for CT and MRI classification. Acta Biomed. 2020;91(8–S):34–42. doi:10.23750/abm.v91i8-S.9971
   Google Scholar
• Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl4):iv30–iv40. doi:10.1093/annonc/mdy133
   Web of Science ®Google Scholar
• Ulutin HC, Oztürk B, Ongürü O, Kuzhan O, Arpaci F, Ozet A. Treatment of primary cutaneous B-cell lymphoma with radiotherapy. Radiat Med. 2005;23(4):292–295.
   Google Scholar
• Oertel M, Elsayad K, Weishaupt C, Steinbrink K, Eich HT. De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma. Strahlenther Onkol. 2020;196(2):126–131. doi:10.1007/s00066-019-01541-7
   PubMed Web of Science ®Google Scholar
• Goyal A, Carter JB, Pashtan I, et al. Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: a retrospective study. J Am Acad Dermatol. 2018;78(2):408–410. doi:10.1016/j.jaad.2017.07.053
   PubMed Web of Science ®Google Scholar
• Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol. 2010;163(1):223–225. doi:10.1111/j.1365-2133.2010.09798.x
   Web of Science ®Google Scholar
• Sica A, Vitiello P, Papa A, et al. Use of rituximab in NHL malt type pregnant in I° trimester for two times. Open Med (Wars). 2019;14:757–760. doi:10.1515/med-2019-0087
   Google Scholar
• Peñate Y, Hernández-Machín B, Pérez-Méndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish working group on cutaneous lymphoma. Br J Dermatol. 2012;167:174–179. doi:10.1111/j.1365-2133.2012.10902.x
   Web of Science ®Google Scholar
• Dreno B, Urosevic-Maiwald M, Kim Y, et al. TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a Phase II clinical trial. PLoS One. 2014;9(2):e83670. doi:10.1371/journal.pone.0083670
   Web of Science ®Google Scholar
• Monari P, Farisoglio C, Calzavara Pinton PG. Borrelia Burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology. 2007;215(3):229–232. doi:10.1159/000106580
   Web of Science ®Google Scholar
• Valencak J, Weihsengruber F, Rappersberger K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol. 2009;20(2):326–330. doi:10.1093/annonc/mdn636
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. doi:10.1200/JCO.19.00010
   PubMed Web of Science ®Google Scholar
• Sica A, Sagnelli C, Papa A, et al. An anecdotal case report of chronic lymphatic leukemia with del(11q) treated with ibrutinib: artificial nourishment and physical activity program. Int J Environ Res Public Health. 2020;17(6):1929. doi:10.3390/ijerph17061929
   Web of Science ®Google Scholar
• Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2020. doi:10.1038/s41375-020-01013-3
   Web of Science ®Google Scholar
• Wagner-Johnston ND, Schuster SJ, deVos S, et al. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leuk Lymphoma. 2020;10:1–11. doi:10.1080/10428194.2020.1855344
   Web of Science ®Google Scholar